Skip to Content

'
Elias Jabbour, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005 Saint Joseph University School of Medicine, Beirut, Lebanon, Fellow, Specialty Diploma, Hematology-Oncology
2003 University of Paris V School of Medicine, Paris, France, University Diploma, Hematology (Clinic and Biologic Options)
2002 University of Paris XI School of Medicine, Paris, France, University Diploma, Clinical Carcinology
1999 Educational Committee for Foreign Medical Graduates, Philadelphia, PA, Certificate, MD
1999 Saint Joseph University, Beirut, Lebanon, Masters, Biologic Sciences
1998 Saint Joseph University, Beirut, Lebanon, MD, MD

Postgraduate Training

11/2005-10/2007 Clinical Fellowship, Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, Richard Champlin, M.D.
11/2003-10/2005 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Hagop Kantarjian, M.D.
11/2001-10/2003 Clinical Fellowship, Hematology-Oncology, Gustave Roussy Institute, Villejiuf, France, Vincent Ribrag, M.D.
7/1998-10/2001 Clinical Residency, Saint Joseph University, Beirut, Lebanon, Marwan Ghosn, M.D.

Board Certifications

1/2010 Lebanese Board of Hematology
1/2010 Lebanese Board of Oncology

Honors and Awards

2007 Merit Award, American Society of Clinical Oncology
2007 Merit Award, American Society of Hematology
2007 The Celegene Future Leader in Hematology Award
2007 The Kimberly Patterson Fellowship in Leukemia Research Award
2007 The Shannon Timmins Fellowship for Leukemia Research Award
2006 Merit Award, American Society of Blood and Marrow Transplantation
2006 Merit Award, American Society of Clinical Oncology
2006 Merit Award, American Society of Hematology
2005 Merit Award, American Society of Clinical Oncolgy
2005 Merit Award, American Society of Hematology

Selected Publications

Peer-Reviewed Original Research Articles
1. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 5/2009. PMID: 19235255.
2. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist 14(5):489-96, 5/2009. e-Pub 4/2009. PMID: 19365094.
3. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res 33(4):565-6, 4/2009. e-Pub 6/2008. PMID: 18571231.
4. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-60, 3/2009. e-Pub 12/2008. PMID: 19060245.
5. Jabbour E, Verstovsek S. Treatment of Myelofibrosis in younger patients: to transplant or not? Am J Hematol 84(3):131-2, 3/2009. PMID: 19202548.
6. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
7. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 84(2):161-9, 2/2009. PMCID: PMC2664587.
8. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1):3-10, 1/2009. e-Pub 1/2009. PMID: 19343297.
9. Fava C, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2:233-43, 2009. PMCID: PMC2761189.
10. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. e-Pub 9/2008.
11. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E , Breeden M, Giles FJ, Zhao W, Kantarjian HM.. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113(5):985-94, 9/2008. e-Pub 7/2008. PMID: 18615627.
12. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E , McMannis J, Champlin R, Shpall E.. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 8/2008. PMID: 18640568.
13. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E , McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution anaylsis. Biol Blood Marrow Transplant 14(8):859-66, 8/2008.
14. Jabbour E, El Ahdab S, Cortes J, Kantarjian H.. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs 17(7):1127-36, 7/2008. PMID: 18549348.
15. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008 Apr 10, 4/2008.
16. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1). e-Pub 4/2008. PMID: 18403620.
17. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H.. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11):2341-51, 4/2008. PMID: 18398832.
18. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer, 2008 Mar 17, 3/2008.
19. Jabbour E, Cortés JE, Kantarjian H. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma 8 Suppl 3:S75-81, 3/2008. PMID: 19254884.
20. Jabbour E, J, Cortes JE, Kantarjian H, Quintas-Cardama A, Radich JP, Bixby DL, Talpaz M, Snead JL, O'Hare T, Eide CA, Deininger MW. Optimizing Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A New Era. Clinical Lymphoma & Myeloma Supplement 8(Supplement 3), March 2008, 3/2008.
21. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112(5):1089-95, 3/2008. PMID: 18186499.
22. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overlook in the treatment of patients with myelodysplastic syndromes. Cancer, 1/2008.
23. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Reviews 8:99-110, 1/2008.
24. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005-11, 12/2007.
25. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991-2995, 10/2007.
26. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a Phase 2 Study. Cancer 110:2012-2018, 9/2007.
27. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110:1295-1302, 9/2007.
28. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40:431-435, 9/2007.
29. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia 21:1347-52, 7/2007.
30. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 10:468-479, 7/2007.
31. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110:340-4, 7/2007.
32. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 109:2171-81, 6/2007.
33. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes 10: Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109:2481-9, 6/2007.
34. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs. 16:679-87, 5/2007.
35. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 21:653-668, 5/2007.
36. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214-8, 4/2007.
37. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs 16:381-92, 3/2007.
38. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 7:S51-7, 3/2007.
39. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 44(1 Suppl 1):S1-3, 1/2007. PMID: 17292735.
40. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E , Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109:265-73, 1/2007.
41. Jabbour E. and Kantarjian H. Integrating the new generation of targeted therapies for chronic myelogenous leukemia - Introduction. Seminars in Hematology 44:S1-S3, 2007.
42. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, and Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges. Clinical Lymphoma & Myeloma 7:S51-S57, 2007.
43. Jabbour E, Cortes J, O'Brien S, Giles F, and Kantarjian H. New targeted therapies for chronic myelogenous leukemia: Opportunities to overcome imatinib resistance. Seminars in Hematology 44:S25-S31, 2007.
44. Thomas DA, Jabbour E, Kantarjian H, and O'Brien S. Response: Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen. Blood 110:1698-1699, 2007.
45. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 18:578-83, 11/2006.
46. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, and Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107:1525-1529, 10/2006.
47. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 5(9):717-8, 9/2006. PMID: 17001803.
48. Jabbour E, Kantarjian H. Impact of Iron Overload and Transfusion Dependence in Patients With Myelodysplastic Syndromes. Clinical Implications of Anemia 3(1):7-9, 4/2006.
49. Jabbour E, Estey E, Kantarjian H. Adult acute Myeloid Leukemia. Proceedings of the Mayo Clinic 81:247-260, 2006.
50. Quintas-Cardama A, Kantarjian H, Jones D, Talpaz M, Jabbour E, O'Brien S, Luthra R, Wierda W, Nicaise C, and Cortes J. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Journal of Clinical Oncology 24:343S, 2006.
51. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, and Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767-1773, 2006.
52. Kantarjian H, Jabbour E, Grimley J, and Kirkpatrick P. Fresh from the pipeline - Dasatinib. Nature Reviews Drug Discovery 5:717-718, 2006.
53. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Ferme C, Bourhis JH, Vantelon JM, Arnaud P, and Ribrag V. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20:814-819, 2006.
54. Jabbour E, Giles F, Cortes J, O'Brien S, Ravandi F, Borthakur G, Garcia-Manero G, Letvak L, Salvado A, and Kantarjian H. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Journal of Clinical Oncology 24:358S, 2006.
55. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan JQ, and Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006.
56. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, and Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480-482, 2006.
57. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan JQ, O'Brien S, Albitar M, and Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. British Journal of Haematology 134:58-60, 2006.
58. Yee KWL, Jabbour E, Kantarjian HM, and Giles F.J. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Annals of Hematology 84:18-24, 12/2005.
59. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, and Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clinical Cancer Research 11:7817-7824, 11/2005.
60. Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, and Ribrag V. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. British Journal of Haematology 131:468-471, 11/2005.
61. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson GE, Kantarjian H, and Andreeff M. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104:541-546, 8/2005.
62. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, and Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia - Final results of a phase II study initiated in 1986. Cancer 103:2551-2557, 6/2005.
63. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, and Ribrag V. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leukemia & Lymphoma 46:861-867, 6/2005.
64. Jabbour E. and Ribrag V. Acute tumor lysis syndrome: update on therapy. Revue de Medecine Interne 26:27-32, 1/2005.
65. Jabbour E, Faderl S, Kantarjian H. Adult acute Lymphoblastic leukemia. Proceedings of the Mayo Clinic 80:1517-1527, 2005.
66. Jabbour E, Kantarjian HM, Garcia-Manero G, Issa JP. Decitabine in myelodysplastic syndromes. Expert Review 2:835-842, 2005.
67. Jabbour E, Yee K, Giles, F. FLT-3 receptor tyrosine kinase as a drug target in leukemia. Future Oncology 1:323-333, 2005.
68. Jabbour E, Giles F. New agents in Myelodysplastic syndromes. Curr Hematol Rep. 4:191-199, 2005.
69. Jabbour E, Kantarjian H, and Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: Possible mechanisms of action. Leukemia & Lymphoma 45:2187-2195, 11/2004.
70. Jabbour E, Keating MJ, Champlin RE, and Khouri I. F. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplantation 34:289-297, 8/2004.
71. Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Ferme C, Carde P, and Ribrag V. Outcome of elderly patients with aggressive non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure. Leukemia & Lymphoma 45:1391-1394, 7/2004.
72. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Faderl S, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, and Issa J.P. Results of a phase I/II study of the combination of 5-aza-2 ' deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia. Blood 104:78A-79A, 2004.
73. Abboud B, Jabbour E, Chahine G. Castelman's disease. Report of two cases with review of the literature. J. Med Liban 49:342-346, 2001.
74. Tabchi B, Rassi S, Jabbour E, Haddad A, Ne Hme P, el Rassi B. Otosclerosis: experience at the Hotel-Dieu in France. J. Med Liban 48:131-135, 2000.

Invited Articles
1. Jabbour E . Improving Outcomes of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia. The American Journal of Hematology/Oncology V6 No 12 Supplement 14, 12/2007.
2. Jabbour E, Kantarjian HM. Thrombocytopenia and Myelodysplastic Syndrom: Epidemiology, Clinical Consequences, and Management Approaches. An Expert Column for: MEDSCPAE CME SPECIAL REPORT Evolving Concepts in Thrombocytopenia, 10/2007.

Editorials
1. Kadia T, Jabbour E , O'Brien S. Treatment strategies for chronic lymphocytic leukemia. US Oncological Disease, 2006.

Abstracts
1. Fava C, Kantarjian HM, Jabbour E , O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21). e-Pub 3/2009. PMID: 19282457.
2. Jabbour E. Clinical characteristics and outcome of patients (pts) with V299L BCR-ABL kinase domain (kd) mutation after therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 12/2008.
3. Jabbour E . Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia Chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). Blood, 12/2008.
4. Jabbour E . Increase in the incidence of Secondary Acute Myeloid Leukemia (2-AML): A single institution experience over 20 years. Blood, 12/2008.
5. Jabbour E . Long-term efficacy of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients (pts) with advanced Chronic Myeloid Leukemia (CML) post imatinib failure. Blood, 12/2008.
6. Jabbour E. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or accerlerated phase (CML-AP). Blood, 12/2008.
7. Jabbour E. Outcome of patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) post decitabine failure. Blood, 12/2008.
8. Jabbour E. . Results of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for advanced Chronic Myeloid Leukemia (CML) patients (pts) who failed Tyrosine Kinase Inhibitors (TKIs) after developing BCR-ABL kinase domain (kd) mutations. Blood, 12/2008.
9. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13). e-Pub 9/2008. PMID: 18818391.
10. Jabbour E . Characteristics and Outcome of Patients with Chronic Myeloid Leukemia (CML) and T315I Mutation Following Failure of Imatinib Mesylate Therapy. Blood, 12/2007.
11. Jabbour E . Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) after Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 12/2007.
12. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer Journal 6:357-65, 12/2007.
13. Jabbour E . Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations. Blood, 12/2007.
14. Jabbour E. Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood, 12/2007.
15. Jabbour E . In Vitro Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations. Blood, 12/2007.
16. Jabbour E . Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). Blood, 12/2007.
17. DeLima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazibash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Anderson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 11/2007. e-Pub 11/2007.
18. Jabbour E Cortes J, Kantarjian H, Giralt S, Champlin R, and de Lima M. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Biology of Blood and Marrow Transplantation 13:91, 2007.
19. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, and de Lima M. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108:1421-1423, 8/2006.
20. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, and Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at MD Anderson Cancer Center. Blood 107:880-884, 2/2006.
21. Jabbour E, Kantarjian H, Abruzzo L, Giles F, Rios MB, and Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during novel tyrosine kinase inhibitors (NTKI) therapy in patients (pts) with chronic myeloid leukemia (CML) after imatinib-failure. Blood 108:600A, 2006.
22. Jabbour E, Kantarjian H, Jones D, Giles F, Borthakur G, O'Brien S, and Cortes J. Clinical characteristics and outcome of patients (pts) with T315I mutation after imatinib failure. Blood 108:621A, 2006.
23. Jabbour E, Kantarjian H, Ravandi-Kashani F, Garcia-Manero G, O'Brien S, and Cortes J. Clinical significance of loss of chromosome Y (-Y) in patients with chronic myeloid leukemia (CML): Is it clonal evolution?. Blood 108:600A, 2006.
24. Giles F, Borthakur G, Ravandi F, Verstovsek S, Pierce S, Jabbour E , Cortes J, and Kantajian H. Comorbidity scoring using the hematopoetic cell transplantation comorbidity index (HCTCI) is predictive of early death rate and event free survival (EFS) in patients over 60 years of age receiving induction therapy for acute mycloid leukemia (AML). Blood 108:559A, 2006.
25. Atallah E, Durand JB, Kantarjian H, Jabbour E, O'Brien S, Rios MB, and Cortes J. Congestive heart failure is a rare event in patients (pts) receiving imatinib therapy. Blood 108:609A, 2006.
26. Jabbour E, O'Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa JP, and Kantarjian H.M. Decitabine induces high response rates in patients with chronic myelomonocytic leukemia (CMML). Blood 108:750A, 2006.
27. Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, and Kantarjian H.M. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy. Blood 108:157A, 2006.
28. Jabbour E, Jones D, Kantarjian H, O'Brien S, Garcia-Manero G, Giles F, Wierda W, and Cortes J. Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI). Blood 108:225A, 2006.
29. Jabbour E, Cortes J, Kantarjian H, Giralt S, Giles F, Anderson BS, Champlin R, and de Lima M. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Blood 108:407B, 2006.
30. Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, and Verstovsek S. PEG-Intron therapy in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPD): Final result of a phase II study. Blood 108:1039A, 2006.
31. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, and Issa J.P. Phase 1/2 study of the combination of 5-aza-2 '-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006.
32. Jabbour E, Hosing C, Pro B, Khouri I, Younes A, Champlin R, and Fayad L. Pre-transplant positive pet/gallium scans predict poor outcome in relapsed/refractory hodgkin lymphoma (HL). Biology of Blood and Marrow Transplantation 12:114-115, 2006.
33. Jabbour E, Cortes J, Giles F, O'Brien S, Letvak L, and Kantarjian H. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Blood 108:616A, 2006.
34. Jabbour E, Kantarjian HM, Cortes J, Wierda WG, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, and Issa J.P. Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with higher risk myelodysplastic syndrome (MDS). Blood 108:749A-750A, 2006.
35. Jabbour E , Cortes J, de Lima M, Anderson B, Giralt S, Kantarjian H, and Champlin R. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing Bcr-Abl kinase mutations with allogeneic stem cell transplantation (ASCT). Biology of Blood and Marrow Transplantation 12:18, 2006.
36. Champlin RE, Jabbour E , Cortes J, Kantarjian H, Anderson BS, Giralt S, and de Lima M. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT). Journal of Clinical Oncology 24:348S, 2006.
37. Jabbour E, Kantarjian H, Giles F, O'Brien S, and Cortes J. . Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib. Blood 108:616A, 2006.
38. Jabbour E, Kantarjian H, O'Brien S, Verstovsek S, Garcia-Manero G, Rios MB, and Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during imatinib mesylate (IM) therapy in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. Blood 106:317A-318A, 2005.
39. Jabbour E, Cortes J, Talpaz M, Jones D, O'Brien S, Nicaise C, and Kantarjian H. Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC). Blood 106:318A, 2005.
40. Jabbour E, Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan JQ, Plunkett W, Keating M, and Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Blood 106:710A, 2005.
41. Jabbour E, Kantarjian H, Talpaz M, Jones D, O'Brien S, Giles F, Garcia-Manero G, Ravandi F, Faderl S, Verstovsek S, Rios MB, and Cortes J. Outcome of salvage therapy in patients (pts) with chronic myeloid leukemia (CML) who failed imatinib after developing BCR-ABL kinase mutation. Blood 106:318A, 2005.
42. Jabbour E, Hosing C, Pro B, Khouri I, and Fayad L. Positive pre-transplant PET/GA67 scan (GA) predicts poor outcome in refractory and relapse Hodgkin's lymphoma (HL). Annals of Oncology 16:121, 2005.
43. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, and Fayad L.E. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin's lymphoma (HL). Journal of Clinical Oncology 23:562S, 2005.
44. Jabbour E, Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan JQ, and Estey E. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Blood 106:525A, 2005.
45. Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, and Andreeff M. 2 chlorodeoxyadenosine (2-CdA) and cytarabine (ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome (HES). Blood 104:274B, 2004.
46. Jabbour E, Kantarjian H, Verstovsek S, Jones D, O'Brien S, Luthra R, Ravandi-Kashani F, Wierda W, Giles F, Rios MB, and Cortes J. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A phase II trial. Blood 104:271B, 2004.
47. Oki Y, Jabbour E, Kantarjian H, Estey E, Cortes JE, Faderl S, Pierce S, Zhou X, Bekele BN, and Garcia-Manero G. Intracranial hemorrhage (ICH) in patients (pts) with newly diagnosed leukemia: Incidence and effect on outcome. Blood 104:216B, 2004.
48. Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, and Cortes J. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome. Blood 104:288A, 2004.
49. Jabbour E, Peslin N, Sebban C, Patte C, Gargi T, Ferme C, Bourhis JH, Vantelon JM, Arnaud P, and Vincent R. High survival rate with modified LMT-81 regimen in lymphoblastic lymphoma (LL). Blood 102:405A, 2003.
50. Jabbour E, Peslin N, Arnaud P, Carde P, Vantelon JM, Bocaccio C, Ferme C, Bourhis JH, and Vincent R. Prognostic value of IPI assessed before high dose salvage therapy in chemosensitive relapsed aggressive lymphomas (NHL). Blood 102:481B, 2003.

Book Chapters
1. Jabbour E., Faderl S, Kantarjian H. Adult acute lymphocytic leukemia. In: The MD Anderson manual of clinical oncology. Kantarjian H, Koller C, Wolff R (Eds.),. McGraw-Hill: New York. In Press.
2. Jabbour E , Kantarjian H, Cortes J. Chronic myeloid leukemia: frontline-current treatment options. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. Taylor and Francis: New York. In Press.
3. Jabbour E, Cortes J, Kantarjian H. Chronic myeloid leukemia: new targeted therapies. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. Taylor and Francis: New York. In Press.
4. Jabbour E , Cortes J, Kantarjian H. Targeted therapy in cancer: chronic myeloid leukemia. In: Targeted therapy in cancer. Razelle Kurzrock and Maurie Markman (Eds),. The Humana Press: New Jersey. In Press.

Last updated: 10/12/2010